Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, ≥ 18 years of age.
Breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastasis only.
HER-2 negative disease.
Candidates for chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
You may not be if
Previous chemotherapy for metastatic or locally advanced breast cancer.
Previous radiotherapy for treatment of metastatic breast cancer.
Any prior adjuvant treatment with anthracyclines completed \< 6 months prior to enrollment.
Chronic daily treatment with corticosteroids (≥ 10 mg/day), aspirin (\> 325 mg/day) or clopidogrel (\> 75mg/day).
Clareo Health | A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
